Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Minqi Cai, Qian Zheng, Yiqiang Chen, Siyuan Liu, Huimin Zhu, Bing Bai
Netrin-1 was initially discovered as a neuronal growth cue for axonal guidance, and its functions have later been identified in inflammation, tumorigenesis, neurodegeneration, and other disorders. We have recently found its alterations in the brains with Alzheimer's disease, which might provide important clues to the mechanisms of some unique pathologies. To provide better understanding of this promising molecule, we here summarize research progresses in genetics, pathology, biochemistry, cell biology and other studies of Netrin-1 about its mechanistic roles and biomarker potentials with an emphasis on clinical neurodegenerative disorders in order to expand understanding of this promising molecular player in human diseases...
2024: Frontiers in Molecular Neuroscience
#22
JOURNAL ARTICLE
Gabriella Miles, Melvyn Smith, Nancy Zook, Wenhao Zhang
Alzheimer's Disease is the most prevalent neurodegenerative disease, and is a leading cause of disability among the elderly. Eye movement behaviour demonstrates potential as a non-invasive biomarker for Alzheimer's Disease, with changes detectable at an early stage after initial onset. This paper introduces a new publicly available dataset: EM-COGLOAD (available at https://osf.io/zjtdq/, DOI: 10.17605/OSF.IO/ZJTDQ). A dual-task paradigm was used to create effects of declined cognitive performance in 75 healthy adults as they carried out visual tracking tasks...
December 2024: Computational and Structural Biotechnology Journal
#23
JOURNAL ARTICLE
Pascual Sánchez-Juan, Elizabeth Valeriano-Lorenzo, Alicia Ruiz-González, Ana Belén Pastor, Hector Rodrigo Lara, Francisco López-González, María Ascensión Zea-Sevilla, Meritxell Valentí, Belen Frades, Paloma Ruiz, Laura Saiz, Iván Burgueño-García, Miguel Calero, Teodoro Del Ser, Alberto Rábano
Glial fibrillary acidic protein (GFAP), a proxy of astrocyte reactivity, has been proposed as biomarker of Alzheimer's disease. However, there is limited information about the correlation between blood biomarkers and post-mortem neuropathology. In a single-centre prospective clinicopathological cohort of 139 dementia patients, for which the time-frame between GFAP level determination and neuropathological assessment was exceptionally short (on average 139 days), we analysed this biomarker, measured at three time points, in relation to proxies of disease progression such as cognitive decline and brain weight...
April 18, 2024: Brain
#24
JOURNAL ARTICLE
Jian Kong, Xu Lin, Bin Wang, Shanling Xu, Yuanlong Wang, Shuhui Hua, Hongyan Gong, Rui Dong, Yanan Lin, Chuan Li, Yanlin Bi
OBJECTIVE: This study aims to explore the relationship between physical activity (PA) and postoperative delirium (POD). METHODS: We selected 400 patients from the Perioperative Neurocognitive Disorder and Biomarkers Lifestyle (PNDABLE) database, and the patients in the PNDABLE database were sampled and tested Alzheimer's biomarkers. The diagnosis of POD was made using the Confusion Assessment Scale (CAM) and the severity was assessed using Memorial Delirium Assessment Scale (MDAS)...
2024: Frontiers in Aging Neuroscience
#25
JOURNAL ARTICLE
Satya P Singh, Sukrit Gupta, Jagath C Rajapakse
Brain state classification by applying deep learning techniques on neuroimaging data has become a recent topic of research. However, unlike domains where the data is low dimensional or there are large number of available training samples, neuroimaging data is high dimensional and has few training samples. To tackle these issues, we present a sparse feedforward deep neural architecture for encoding and decoding the structural connectome of the human brain. We use a sparsely connected element-wise multiplication as the first hidden layer and a fixed transform layer as the output layer...
2024: IEEE Journal of Translational Engineering in Health and Medicine
#26
JOURNAL ARTICLE
Julie K Wisch, Nicole S McKay, Anna H Boerwinkle, James Kennedy, Shaney Flores, Benjamin L Handen, Bradley T Christian, Elizabeth Head, Mark Mapstone, Michael S Rafii, Sid E O'Bryant, Julie C Price, Charles M Laymon, Sharon J Krinsky-McHale, Florence Lai, H Diana Rosas, Sigan L Hartley, Shahid Zaman, Ira T Lott, Dana Tudorascu, Matthew Zammit, Adam M Brickman, Joseph H Lee, Thomas D Bird, Annie Cohen, Patricio Chrem, Alisha Daniels, Jasmeer P Chhatwal, Carlos Cruchaga, Laura Ibanez, Mathias Jucker, Celeste M Karch, Gregory S Day, Jae-Hong Lee, Johannes Levin, Jorge Llibre-Guerra, Yan Li, Francisco Lopera, Jee Hoon Roh, John M Ringman, Charlene Supnet-Bell, Christopher H van Dyck, Chengjie Xiong, Guoqiao Wang, John C Morris, Eric McDade, Randall J Bateman, Tammie L S Benzinger, Brian A Gordon, Beau M Ances
BACKGROUND: In people with genetic forms of Alzheimer's disease, such as in Down syndrome and autosomal-dominant Alzheimer's disease, pathological changes specific to Alzheimer's disease (ie, accumulation of amyloid and tau) occur in the brain at a young age, when comorbidities related to ageing are not present. Studies including these cohorts could, therefore, improve our understanding of the early pathogenesis of Alzheimer's disease and be useful when designing preventive interventions targeted at disease pathology or when planning clinical trials...
May 2024: Lancet Neurology
#27
JOURNAL ARTICLE
Qi Zhang, Fangjie Li, Min Wei, Min Wang, Luyao Wang, Ying Han, Jiehui Jiang
BACKGROUND: Predicting cognitive decline in those already Aβ positive or Tau positive among the aging population poses clinical challenges. In Alzheimer's disease (AD) research, intra-default mode network (DMN) connections play a pivotal role in diagnosis. This paper proposes metabolic connectivity within the DMN as a supplementary biomarker to the AT(N) framework. METHODS: Extracting data from 1292 subjects in the Alzheimer's Disease Neuroimaging Initiative, we collected paired T1-weighted structural MRI and 18 F-labeled-fluorodeoxyglucose positron emission computed tomography (PET) scans...
April 15, 2024: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
#28
REVIEW
Marcel Pérez-Morales, Paola C Bello-Medina, Diego A González-Franco, Sofía Díaz-Cintra, Jaime García-Mena, Gustavo Pacheco-López
BACKGROUND: Over the last century, animal models have been employed to study the gut-brain axis and its relationship with physiological processes, including those necessary for survival, such as food intake regulation and thermoregulation; those involved in diseases, ranging from inflammation to obesity; and those concerned to the development of neurodegenerative diseases and neuropsychiatric disorders, such as Alzheimer's disease and autism spectrum disorder, respectively. SUMMARY: The gut microbiota has been recognized in the last decade as an essential functional component of this axis...
April 17, 2024: Neuroimmunomodulation
#29
JOURNAL ARTICLE
Bogyeom Park, Yuwon Kim, Jinseok Park, Hojin Choi, Seong-Eun Kim, Hokyoung Ryu, Kyoungwon Seo
BACKGROUND: Early detection of mild cognitive impairment (MCI), a transitional stage between normal aging and Alzheimer disease, is crucial for preventing the progression of dementia. Virtual reality (VR) biomarkers have proven to be effective in capturing behaviors associated with subtle deficits in instrumental activities of daily living, such as challenges in using a food-ordering kiosk, for early detection of MCI. On the other hand, magnetic resonance imaging (MRI) biomarkers have demonstrated their efficacy in quantifying observable structural brain changes that can aid in early MCI detection...
April 17, 2024: Journal of Medical Internet Research
#30
JOURNAL ARTICLE
Homa Seyedmirzaei, Amirhossein Salmannezhad, Hamidreza Ashayeri, Ali Shushtari, Bita Farazinia, Mohammad Mahdi Heidari, Amirali Momayezi, Sara Shaki Baher
Growth-associated protein 43 (GAP-43) is found in the axonal terminal of neurons in the limbic system, which is affected in people with Alzheimer's disease (AD). We assumed GAP-43 may contribute to AD progression and serve as a biomarker. So, in a two-year follow-up study, we assessed GAP-43 changes and whether they are correlated with tensor-based morphometry (TBM) findings in patients with mild cognitive impairment (MCI). We included MCI and cognitively normal (CN) people with available baseline and follow-up cerebrospinal fluid (CSF) GAP-43 and TBM findings from the ADNI database...
April 17, 2024: Neuroinformatics
#31
JOURNAL ARTICLE
Doris Patricia Molina-Henry, Rema Raman, Andy Liu, Oliver Langford, Keith Johnson, Leona K Shum, Crystal M Glover, Shobha Dhadda, Michael Irizarry, Gustavo Jimenez-Maggiora, Joel B Braunstein, Kevin Yarasheski, Venky Venkatesh, Tim West, Philip B Verghese, Robert A Rissman, Paul Aisen, Joshua D Grill, Reisa A Sperling
INTRODUCTION: In trials of amyloid-lowering drugs for Alzheimer's disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron emission tomography (PET) amyloid eligibility for the ongoing AHEAD Study preclinical AD program (NCT04468659). METHODS: Univariate logistic regression models were used to examine group differences in plasma and PET amyloid screening eligibility...
April 17, 2024: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
#32
JOURNAL ARTICLE
Longjian Liu, Edward J Gracely, Xiaopeng Zhao, Gediminas P Gliebus, Nathalie S May, Stella L Volpe, Jingyi Shi, Rose Ann DiMaria-Ghalili, Howard J Eisen
BACKGROUND AND OBJECTIVES: There is a scarcity of data stemming from large-scale epidemiological longitudinal studies focusing on potentially preventable and controllable risk factors for Alzheimer's disease (AD) and AD-related dementia (ADRD). This study aimed to examine the effect of multiple metabolic factors and cardiovascular disorders on the risk of cognitive decline and AD/ADRD. METHODS: We analyzed a cohort of 6,440 participants aged 45-84 years at baseline...
2024: Frontiers in Aging Neuroscience
#33
JOURNAL ARTICLE
Saumya Ranjan Pradhan, Ramadevi Suguru Pathinti, Ramesh Kandimalla, Krishnakanth Chithari, Madhava Rao Veeramalla N, Jayalakshmi Vallamkondu
This study introduces a biosensor based on liquid crystals (LC) designed to detect the Aβ-42 biomarker, commonly associated with Alzheimer's disease. The sensor utilizes LC droplets created using a PEI/Tween-20 surfactant mixture, arranged radially in an aqueous solution. These droplets are coated with the Aβ1-16 antibody, enabling the detection of the Aβ1-42 biomarker. The key advantage of this biosensor lies in its ability to directly translate the antigen-antibody interaction into a change in the molecular orientation of the LC droplets, simplifying the detection process by removing additional procedural steps...
April 10, 2024: RSC Advances
#34
JOURNAL ARTICLE
Juan Felipe Martínez-Flórez, Mateo Belalcázar, Alexandrina Alvarez, Oscar Erazo, SairyTupak Sevilla, Mario Alfredo Parra
Objective: The Visual Short-Term Memory Binding (VSTMB) Test is a useful tool in the assessment of Alzheimer's disease (AD). Research has suggested that short-term memory binding is insensitive to the sociocultural characteristics of the assessed individuals. Such earlier studies addressed this influence by considering years of education. The current study aims to determine the influence of sociocultural factors via a measure of Socioeconomic Status (SES) which provides a more holistic approach to these common confounders...
April 16, 2024: Clinical Neuropsychologist
#35
JOURNAL ARTICLE
Zhen Liu, Dai Shi, Yue Cai, Anqi Li, Guoyu Lan, Pan Sun, Lin Liu, Yalin Zhu, Jie Yang, Yajing Zhou, Lizhi Guo, Laihong Zhang, Shuqing Deng, Shuda Chen, Xianfeng Yu, Xuhui Chen, Ruiyue Zhao, Qingyong Wang, Pengcheng Ran, Linsen Xu, Liemin Zhou, Kun Sun, Xinlu Wang, Qiyu Peng, Ying Han, Tengfei Guo
INTRODUCTION: The Guangdong-Hong Kong-Macao Greater-Bay-Area of South China has an 86 million population and faces a significant challenge of Alzheimer's disease (AD). However, the characteristics and prevalence of AD in this area are still unclear due to the rarely available community-based neuroimaging AD cohort. METHODS: Following the standard protocols of the Alzheimer's Disease Neuroimaging Initiative, the Greater-Bay-Area Healthy Aging Brain Study (GHABS) was initiated in 2021...
April 16, 2024: Alzheimer's Research & Therapy
#36
JOURNAL ARTICLE
Cynthia Yi-An Chen, Chih-Chiang Chiu, Cho-Yin Huang, Ying-Chih Cheng, Ming-Chyi Huang, Po-Hsiu Kuo, Wen-Yin Chen
BACKGROUND: Cognitive impairment is a growing problem with increasing burden in global aging. Older adults with major depressive disorder (MDD) have higher risk of dementia. Neurofilament light chain (NfL) has been proven as a potential biomarker in neurodegenerative disease, including dementia. We aimed to investigate the association between cognitive deficits and NfL levels in older adults with MDD. METHODS: In this cross-sectional study, we enrolled 39 MDD patients and 15 individuals with mild neurocognitive disorder or major neurocognitive disorder, Alzheimer's type, as controls, from a tertiary psychiatric hospital...
April 16, 2024: BMC Geriatrics
#37
JOURNAL ARTICLE
Jane Alty, Lynette R Goldberg, Eddy Roccati, Katherine Lawler, Quan Bai, Guan Huang, Aidan D Bindoff, Renjie Li, Xinyi Wang, Rebecca J St George, Kaylee Rudd, Larissa Bartlett, Jessica M Collins, Mimieveshiofuo Aiyede, Nadeeshani Fernando, Anju Bhagwat, Julia Giffard, Katharine Salmon, Scott McDonald, Anna E King, James C Vickers
BACKGROUND: Dementia prevalence is predicted to triple to 152 million globally by 2050. Alzheimer's disease (AD) constitutes 70% of cases. There is an urgent need to identify individuals with preclinical AD, a 10-20-year period of progressive brain pathology without noticeable cognitive symptoms, for targeted risk reduction. Current tests of AD pathology are either too invasive, specialised or expensive for population-level assessments. Cognitive tests are normal in preclinical AD...
April 16, 2024: BMC Neurology
#38
JOURNAL ARTICLE
Burak Malik Kaya, Semih Oz, Okan Esentürk
A novel fiber optic biosensor was purposed for a new approach to monitor amyloid beta protein fragment 1-42 (Aβ42) for Alzheimer's Disease (AD) early detection. The sensor was fabricated by etching a part of fiber from single mode fiber loop in pure hydrofluoric acid solution and utilized as a Local Optical Refractometer (LOR) to monitor the change Aβ42 concentration in Artificial Cerebrospinal Fluid (ACSF). The Fiber Loop Ringdown Spectroscopy (FLRDS) technique is an ultra-sensitive measurement technique with low-cost, high sensitivity, real-time measurement, continuous measurement and portability features that was utilized with a fiber optic sensor for the first time for the detection of a biological signature in an ACSF environment...
April 16, 2024: Biomedical Physics & Engineering Express
#39
JOURNAL ARTICLE
Leslie Grasset, Vincent Bouteloup, Federica Cacciamani, Isabelle Pellegrin, Vincent Planche, Geneviève Chêne, Carole Dufouil
BACKGROUND AND OBJECTIVES: Elevated levels of Alzheimer disease (AD) blood-based biomarkers are associated with accelerated cognitive decline. However, their distinct relationships with specific cognitive and functional domains require further investigation. We aimed at estimating the associations between AD blood-based biomarkers and the trajectories of distinct cognitive and functional domains over a 5-year follow-up period. METHODS: We conducted a clinic-based prospective study using data from the MEMENTO study, a nationwide French cohort...
May 2024: Neurology
#40
JOURNAL ARTICLE
Maurice Pasternak, Saira S Mirza, Nicholas Luciw, Henri J M M Mutsaerts, Jan Petr, David Thomas, David Cash, Martina Bocchetta, Maria Carmela Tartaglia, Sara B Mitchell, Sandra E Black, Morris Freedman, David Tang-Wai, Ekaterina Rogaeva, Lucy L Russell, Arabella Bouzigues, John C van Swieten, Lize C Jiskoot, Harro Seelaar, Robert Laforce, Pietro Tiraboschi, Barbara Borroni, Daniela Galimberti, James B Rowe, Caroline Graff, Elizabeth Finger, Sandro Sorbi, Alexandre de Mendonça, Chris Butler, Alex Gerhard, Raquel Sanchez-Valle, Fermin Moreno, Matthis Synofzik, Rik Vandenberghe, Simon Ducharme, Johannes Levin, Markus Otto, Isabel Santana, Antonio P Strafella, Bradley J MacIntosh, Jonathan D Rohrer, Mario Masellis
INTRODUCTION: Effective longitudinal biomarkers that track disease progression are needed to characterize the presymptomatic phase of genetic frontotemporal dementia (FTD). We investigate the utility of cerebral perfusion as one such biomarker in presymptomatic FTD mutation carriers. METHODS: We investigated longitudinal profiles of cerebral perfusion using arterial spin labeling magnetic resonance imaging in 42 C9orf72, 70 GRN, and 31 MAPT presymptomatic carriers and 158 non-carrier controls...
April 16, 2024: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
